Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies

NCT04465487 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

38

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor Decision

Conditions

Squamous Cell Carcinoma of Head and Neck

Interventions

DRUG: REGN6569
DRUG: Cemiplimab

Sponsor

Regeneron Pharmaceuticals